HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries.

AbstractOBJECTIVES:
This study aimed to assess the feasibility of preoperative chemoradiotherapy using gemcitabine plus nab-paclitaxel (GnP) and to determine the recommended dose (RD) of nab-paclitaxel for patients with localized pancreatic ductal adenocarcinoma (PDAC).
METHODS:
The participants had localized PDAC with contact or invasion to major arteries. They received GnP on days 1, 15, 29, and 43. The dose of gemcitabine was fixed at 600 mg/m2, whereas that of nab-paclitaxel was at 3 dose levels in accordance with a standard 3 + 3 dose escalation scheme. Three-dimensional radiotherapy was administered concurrently to a total dose of 50.4 Gy per 28 fractions.
RESULTS:
The study cohort comprised 15 patients. Grade 3 or 4 neutropenia was observed in 4 (26.7%), leukopenia in 1 (6.7%), biliary infection in 2 (13.3%), appetite loss and nausea in 1 (6.7%), and anaphylaxis in 1 (6.7%). The RD was determined as level 2 (gemcitabine, 600 mg/m2; nab-paclitaxel, 100 mg/m2). Three patients underwent pancreatectomy after additional chemotherapy and achieved R0 resection.
CONCLUSIONS:
The RD of nab-paclitaxel in our chemoradiotherapy protocol using GnP was 100 mg/m2 with gemcitabine 600 mg/m2 and 3-dimensional conformal radiotherapy to a total dose of 50.4 Gy per 28 fractions for patients with localized PDAC.
AuthorsAoi Hayasaki, Masashi Kishiwada, Yasuhiro Murata, Haruna Komatsubara, Yuki Nakagawa, Koki Maeda, Toru Shinkai, Daisuke Noguchi, Kazuyuki Gyoten, Takehiro Fujii, Yusuke Iizawa, Akihiro Tanemura, Naohisa Kuriyama, Hiroyuki Sakurai, Shuji Isaji, Shugo Mizuno
JournalPancreas (Pancreas) Vol. 50 Issue 8 Pg. 1230-1235 (09 01 2021) ISSN: 1536-4828 [Electronic] United States
PMID34714288 (Publication Type: Clinical Trial, Phase I, Journal Article)
CopyrightCopyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Chemical References
  • 130-nm albumin-bound paclitaxel
  • Albumins
  • Deoxycytidine
  • Paclitaxel
  • Gemcitabine
Topics
  • Aged
  • Aged, 80 and over
  • Albumins (administration & dosage)
  • Arteries (pathology)
  • Carcinoma, Pancreatic Ductal (pathology, surgery, therapy)
  • Chemoradiotherapy (methods)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Paclitaxel (administration & dosage)
  • Pancreatectomy
  • Pancreatic Neoplasms (pathology, surgery, therapy)
  • Vascular Neoplasms (pathology, surgery, therapy)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: